Stoke Therapeutics, Inc.

NasdaqGS:STOK 株式レポート

時価総額:US$677.1m

Stoke Therapeutics 過去の業績

過去 基準チェック /06

Stoke Therapeutics's earnings have been declining at an average annual rate of -25.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 65.9% per year.

主要情報

-25.3%

収益成長率

12.5%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率65.9%
株主資本利益率-42.7%
ネット・マージン-683.3%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Sep 07

We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Jul 22
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome

Jun 14

It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope

May 30
It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope

Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist

Apr 04

Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

Mar 21
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Dec 07
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

May 09
Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

May 06
Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

May 02
Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Dec 13
We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Aug 14
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M

Aug 08

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Apr 29
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

Jan 13
Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Sep 30
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Jun 16
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics EPS misses by $0.02

May 10

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap

Dec 14

収支内訳

Stoke Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:STOK 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 2415-1044486
31 Mar 248-1094185
31 Dec 239-1054182
30 Sep 239-1034082
30 Jun 239-1054081
31 Mar 2315-994079
31 Dec 2212-1013978
30 Sep 229-1003873
30 Jun 226-963767
31 Mar 223-943463
31 Dec 210-863254
30 Sep 210-762947
30 Jun 210-672641
31 Mar 210-582335
31 Dec 200-522132
30 Sep 200-481930
30 Jun 200-431729
31 Mar 200-381427
31 Dec 190-321224
30 Sep 190-26920
30 Jun 190-21715
31 Mar 190-16611
31 Dec 180-1348

質の高い収益: STOK is currently unprofitable.

利益率の向上: STOK is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: STOK is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.

成長の加速: Unable to compare STOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: STOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


株主資本利益率

高いROE: STOK has a negative Return on Equity (-42.67%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘